Genomics-based markers that predict responses to immunotherapy, such as PD-L1 expression, tumor mutational burden and microbiota, have been proposed, but are not used to make clinical decisions due to their poor accuracy [12,13]. The gene discussed is CD274; the disease is neoplasm.